Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study

Aleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Anna Polakiewicz-Gilowska, Renata Soumarová, Miloš Holánek, Hana Študentová, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik-Resko, Tomasz Ciszewski, Lenka Rušinová, Bogumiła Czartoryska-Arłukowicz, Aleksandra Łacko, Michał Jarząb, Marcin Kubeczko, Renata Pacholczak-Madej, Joanna Smok-Kalwat, Zbigniew Nowecki, Zuzana Bielčiková, Miroslava Malejčíková, Mirosława Püsküllüoğlu · 2026

Read Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study by Aleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Anna Polakiewicz-Gilowska, Renata Soumarová, Miloš Holánek, Hana Študentová, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik-Resko, Tomasz Ciszewski, Lenka Rušinová, Bogumiła Czartoryska-Arłukowicz, Aleksandra Łacko, Michał Jarząb, Marcin Kubeczko, Renata Pacholczak-Madej, Joanna Smok-Kalwat, Zbigniew Nowecki, Zuzana Bielčiková, Miroslava Malejčíková, Mirosława Püsküllüoğlu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466717.txt.

Description

Aleksandra Konieczna and co-authors examine how older patients whose breast cancer was metastatic and triple-negative fare on the drug sacituzumab govitecan, an antibody-drug conjugate, outside clinical trials. Older adults are underrepresented in trials, so real-world evidence matters. Their 2026 retrospective study spans eighteen oncology centres in Central Europe and includes patients treated between 2021 and 2025.

Among 303 patients, 76 were aged sixty-five or older. Older patients carried more other illnesses, had received more previous treatment lines, and had worse performance status. Yet in unadjusted analysis they lived longer overall, a median 12.8 months against 10.9, and longer without progression. Response rates, treatment changes, and severe low white cell counts were similar across ages. After statistical adjustment, age itself was not independently linked to survival. The authors conclude selected older patients do at least as well as younger ones, and that selection explains much of the apparent advantage.

Catalog record

CREATORAleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Anna Polakiewicz-Gilowska, Renata Soumarová, Miloš Holánek, Hana Študentová, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik-Resko, Tomasz Ciszewski, Lenka Rušinová, Bogumiła Czartoryska-Arłukowicz, Aleksandra Łacko, Michał Jarząb, Marcin Kubeczko, Renata Pacholczak-Madej, Joanna Smok-Kalwat, Zbigniew Nowecki, Zuzana Bielčiková, Miroslava Malejčíková, Mirosława Püsküllüoğlu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13466717

Browse the full library · About the Tower of Babel